{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T05:28:39Z","timestamp":1783747719321,"version":"3.55.0"},"reference-count":140,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100006447","name":"University of Zurich","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006447","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s40263-022-00944-y","type":"journal-article","created":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T16:07:39Z","timestamp":1662998859000},"page":"1031-1047","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic Review"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4606-3528","authenticated-orcid":false,"given":"Niloufar","family":"Pouyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Halvaei Khankahdani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farnaz","family":"Younesi Sisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yena","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Rosenblat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla M.","family":"Teopiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0148-5455","authenticated-orcid":false,"given":"Leanna M. W.","family":"Lui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehala","family":"Subramaniapillai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangguang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0627-3558","authenticated-orcid":false,"given":"Flora","family":"Nasri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3568-8816","authenticated-orcid":false,"given":"Hartej","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9110-7951","authenticated-orcid":false,"given":"Orly","family":"Lipsitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5963-2676","authenticated-orcid":false,"given":"Bing","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9629-4493","authenticated-orcid":false,"given":"Roger","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Castle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger S.","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,12]]},"reference":[{"key":"944_CR1","doi-asserted-by":"publisher","first-page":"683","DOI":"10.2471\/BLT.20.251405","volume":"98","author":"Y Lee","year":"2020","unstructured":"Lee Y, Brietzke E, Cao B, Chen Y, Linnaranta O, Mansur RB, et al. Development and implementation of guidelines for the management of depression: a systematic review. Bull World Health Organ. 2020;98:683\u201397.","journal-title":"Bull World Health Organ"},{"key":"944_CR2","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/bdi.13026","volume":"22","author":"RS McIntyre","year":"2020","unstructured":"McIntyre RS. In vivo phenotyping, mechanism-informed treatments, domain-based psychopathology and nomological networks: a strategy for treatment discovery and development in bipolar depression. Bipolar Disord. 2020;22:657\u20139.","journal-title":"Bipolar Disord"},{"key":"944_CR3","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1038\/mp.2012.105","volume":"17","author":"S Kapur","year":"2012","unstructured":"Kapur S, Phillips AG, Insel TR. Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it? Mol Psychiatry. 2012;17:1174\u20139.","journal-title":"Mol Psychiatry"},{"key":"944_CR4","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1176\/appi.ajp.2010.09091379","volume":"167","author":"T Insel","year":"2010","unstructured":"Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K, et al. Research Domain Criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry. 2010;167:748\u201351.","journal-title":"Am J Psychiatry"},{"key":"944_CR5","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/psyp.12518","volume":"53","author":"MJ Kozak","year":"2016","unstructured":"Kozak MJ, Cuthbert BN. The NIMH Research Domain Criteria Initiative: background, issues, and pragmatics. Psychophysiology. 2016;53:286\u201397.","journal-title":"Psychophysiology"},{"key":"944_CR6","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.cell.2020.03.020","volume":"181","author":"D Nutt","year":"2020","unstructured":"Nutt D, Erritzoe D, Carhart-Harris R. Psychedelic psychiatry\u2019s brave new world. Cell. 2020;181:24\u20138.","journal-title":"Cell"},{"key":"944_CR7","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1503\/cmaj.141124","volume":"187","author":"KW Tupper","year":"2015","unstructured":"Tupper KW, Wood E, Yensen R, Johnson MW. Psychedelic medicine: a re-emerging therapeutic paradigm. CMAJ. 2015;187:1054\u20139.","journal-title":"CMAJ"},{"key":"944_CR8","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1080\/02791072.1986.10472362","volume":"18","author":"DE Nichols","year":"1986","unstructured":"Nichols DE. Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J Psychoactive Drugs. 1986;18:305\u201313.","journal-title":"J Psychoactive Drugs"},{"key":"944_CR9","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41583-020-0367-2","volume":"21","author":"FX Vollenweider","year":"2020","unstructured":"Vollenweider FX, Preller KH. Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. Nat Rev Neurosci. 2020;21:611\u201324.","journal-title":"Nat Rev Neurosci"},{"key":"944_CR10","doi-asserted-by":"publisher","unstructured":"Preller KH, Vollenweider FX. Phenomenology, structure, and dynamic of psychedelic states. In: Halberstadt AL, Vollenweider FX, Nichols DE, editors. Behavioral neurobiology of psychedelic drugs. Berlin: Springer; 2018. p. 221\u201356. https:\/\/doi.org\/10.1007\/7854_2016_459.","DOI":"10.1007\/7854_2016_459"},{"key":"944_CR11","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1080\/14737175.2020.1826931","volume":"20","author":"H Gill","year":"2020","unstructured":"Gill H, Gill B, Chen-Li D, El-Halabi S, Rodrigues NB, Cha DS, et al. The emerging role of psilocybin and MDMA in the treatment of mental illness. Expert Rev Neurother. 2020;20:1263\u201373.","journal-title":"Expert Rev Neurother"},{"key":"944_CR12","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1093\/ijnp\/pyaa018","volume":"23","author":"E Krediet","year":"2020","unstructured":"Krediet E, Bostoen T, Breeksema J, van Schagen A, Passie T, Vermetten E. Reviewing the potential of psychedelics for the treatment of PTSD. Int J Neuropsychopharmacol. 2020;23:385\u2013400.","journal-title":"Int J Neuropsychopharmacol"},{"key":"944_CR13","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.cobeha.2016.10.009","volume":"13","author":"C Morgan","year":"2017","unstructured":"Morgan C, McAndrew A, Stevens T, Nutt D, Lawn W. Tripping up addiction: the use of psychedelic drugs in the treatment of problematic drug and alcohol use. Curr Opin Behav Sci. 2017;13:71\u20136.","journal-title":"Curr Opin Behav Sci"},{"key":"944_CR14","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1177\/0269881120919957","volume":"34","author":"B Romeo","year":"2020","unstructured":"Romeo B, Karila L, Martelli C, Benyamina A. Efficacy of psychedelic treatments on depressive symptoms: a meta-analysis. J Psychopharmacol. 2020;34:1079\u201385.","journal-title":"J Psychopharmacol"},{"key":"944_CR15","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1002\/da.23065","volume":"37","author":"NM Weston","year":"2020","unstructured":"Weston NM, Gibbs D, Bird CIV, Daniel A, Jelen LA, Knight G, et al. Historic psychedelic drug trials and the treatment of anxiety disorders. Depress Anxiety. 2020;37:1261\u201379.","journal-title":"Depress Anxiety"},{"key":"944_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.800072","volume":"12","author":"JR Kelly","year":"2021","unstructured":"Kelly JR, Gillan CM, Prenderville J, Kelly C, Harkin A, Clarke G, et al. Psychedelic therapy\u2019s transdiagnostic effects: a Research Domain Criteria (RDoC) perspective. Front Psychiatry. 2021;12: 800072.","journal-title":"Front Psychiatry."},{"key":"944_CR17","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","volume":"8","author":"D Moher","year":"2010","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8:336\u201341.","journal-title":"Int J Surg"},{"key":"944_CR18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.neuropharm.2018.02.018","volume":"142","author":"SJ Belouin","year":"2018","unstructured":"Belouin SJ, Henningfield JE. Psychedelics: where we are now, why we got here, what we must do. Neuropharmacology. 2018;142:7\u201319.","journal-title":"Neuropharmacology"},{"key":"944_CR19","unstructured":"Positive Valence Systems. National Institute of Mental Health (NIMH). https:\/\/www.nimh.nih.gov\/research\/research-funded-by-nimh\/rdoc\/constructs\/positive-valence-systems. Accessed 23 May 2022."},{"key":"944_CR20","unstructured":"Negative Valence Systems. National Institute of Mental Health (NIMH). https:\/\/www.nimh.nih.gov\/research\/research-funded-by-nimh\/rdoc\/constructs\/negative-valence-systems. Accessed 9 Jan 2022."},{"key":"944_CR21","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/da.22063","volume":"30","author":"RS McIntyre","year":"2013","unstructured":"McIntyre RS, Cha DS, Soczynska JK, Woldeyohannes HO, Gallaugher LA, Kudlow P, et al. Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions. Depress Anxiety. 2013;30:515\u201327.","journal-title":"Depress Anxiety"},{"key":"944_CR22","unstructured":"National Institute of Mental Health (NIMH). Social processes. https:\/\/www.nimh.nih.gov\/research\/research-funded-by-nimh\/rdoc\/constructs\/social-processes.shtml. Accessed 3 Apr 2021."},{"key":"944_CR23","unstructured":"National Institute of Mental Health (NIMH). Sensorimotor systems. https:\/\/www.nimh.nih.gov\/research\/research-funded-by-nimh\/rdoc\/constructs\/sensorimotor-systems. Accessed 23 May 2022."},{"key":"944_CR24","unstructured":"National Institute of Mental Health (NIMH). Arousal and regulatory systems. https:\/\/www.nimh.nih.gov\/research\/research-funded-by-nimh\/rdoc\/constructs\/arousal-and-regulatory-systems.shtml. Accessed 18 Apr 2021."},{"key":"944_CR25","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s40262-017-0540-6","volume":"56","author":"RT Brown","year":"2017","unstructured":"Brown RT, Nicholas CR, Cozzi NV, Gassman MC, Cooper KM, Muller D, et al. Pharmacokinetics of escalating doses of oral psilocybin in healthy adults. Clin Pharmacokinet. 2017;56:1543\u201354.","journal-title":"Clin Pharmacokinet"},{"key":"944_CR26","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1177\/09637214211051363","volume":"31","author":"BN Cuthbert","year":"2022","unstructured":"Cuthbert BN. Research Domain Criteria (RDoC): progress and potential. Curr Dir Psychol Sci. 2022;31:107\u201314.","journal-title":"Curr Dir Psychol Sci"},{"key":"944_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2020.117049","volume":"220","author":"TF Varley","year":"2020","unstructured":"Varley TF, Carhart-Harris R, Roseman L, Menon DK, Stamatakis EA. Serotonergic psychedelics LSD & psilocybin increase the fractal dimension of cortical brain activity in spatial and temporal domains. Neuroimage. 2020;220: 117049.","journal-title":"Neuroimage"},{"key":"944_CR28","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2174\/1874473708666150107120930","volume":"7","author":"S Turton","year":"2014","unstructured":"Turton S, Nutt DJ, Carhart-Harris RL. A qualitative report on the subjective experience of intravenous psilocybin administered in an FMRI environment. Curr Drug Abuse Rev. 2014;7:117\u201327.","journal-title":"Curr Drug Abuse Rev"},{"key":"944_CR29","doi-asserted-by":"publisher","first-page":"204","DOI":"10.3389\/fnhum.2014.00204","volume":"8","author":"L Roseman","year":"2014","unstructured":"Roseman L, Leech R, Feilding A, Nutt DJ, Carhart-Harris RL. The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers. Front Hum Neurosci. 2014;8:204.","journal-title":"Front Hum Neurosci"},{"key":"944_CR30","doi-asserted-by":"publisher","first-page":"5442","DOI":"10.1002\/hbm.22562","volume":"35","author":"E Tagliazucchi","year":"2014","unstructured":"Tagliazucchi E, Carhart-Harris R, Leech R, Nutt D, Chialvo DR. Enhanced repertoire of brain dynamical states during the psychedelic experience. Hum Brain Mapp. 2014;35:5442\u201356.","journal-title":"Hum Brain Mapp"},{"key":"944_CR31","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1093\/schbul\/sbs117","volume":"39","author":"RL Carhart-Harris","year":"2013","unstructured":"Carhart-Harris RL, Leech R, Erritzoe D, Williams TM, Stone JM, Evans J, et al. Functional connectivity measures after psilocybin inform a novel hypothesis of early psychosis. Schizophr Bull. 2013;39:1337\u201342.","journal-title":"Schizophr Bull"},{"key":"944_CR32","doi-asserted-by":"publisher","first-page":"4982","DOI":"10.1002\/hbm.25174","volume":"41","author":"L Smigielski","year":"2020","unstructured":"Smigielski L, Kometer M, Scheidegger M, Stress C, Preller KH, Koenig T, et al. P300-mediated modulations in self\u2013other processing under psychedelic psilocybin are related to connectedness and changed meaning: a window into the self\u2013other overlap. Hum Brain Mapp. 2020;41:4982\u201396.","journal-title":"Hum Brain Mapp"},{"key":"944_CR33","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.biopsych.2019.12.027","volume":"88","author":"KH Preller","year":"2020","unstructured":"Preller KH, Duerler P, Burt JB, et al. Psilocybin induces time-dependent changes in global functional connectivity. Biol Psychiatry. 2020;88:197\u2013207.","journal-title":"Biol Psychiatry"},{"key":"944_CR34","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1038\/s41386-020-0718-8","volume":"45","author":"NL Mason","year":"2020","unstructured":"Mason NL, Kuypers KPC, M\u00fcller F, Reckweg J, Tse DHY, Toennes SW, et al. Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin. Neuropsychopharmacol. 2020;45:2003\u201311.","journal-title":"Neuropsychopharmacol"},{"key":"944_CR35","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1007\/s00213-020-05533-9","volume":"237","author":"TM Carbonaro","year":"2020","unstructured":"Carbonaro TM, Johnson MW, Griffiths RR. Subjective features of the psilocybin experience that may account for its self-administration by humans: a double-blind comparison of psilocybin and dextromethorphan. Psychopharmacology. 2020;237:2293\u2013304.","journal-title":"Psychopharmacology"},{"key":"944_CR36","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s00213-017-4769-4","volume":"235","author":"TM Carbonaro","year":"2018","unstructured":"Carbonaro TM, Johnson MW, Hurwitz E, Griffiths RR. Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences. Psychopharmacology. 2018;235:521\u201334.","journal-title":"Psychopharmacology"},{"key":"944_CR37","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1007\/s00213-018-4981-x","volume":"235","author":"FS Barrett","year":"2018","unstructured":"Barrett FS, Carbonaro TM, Hurwitz E, Johnson MW, Griffiths RR. Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: effects on cognition. Psychopharmacology. 2018;235:2915\u201327.","journal-title":"Psychopharmacology"},{"key":"944_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2020.116980","volume":"218","author":"FS Barrett","year":"2020","unstructured":"Barrett FS, Krimmel SR, Griffiths RR, Seminowicz DA, Mathur BN. Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention. Neuroimage. 2020;218: 116980.","journal-title":"Neuroimage"},{"key":"944_CR39","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1177\/0269881119897615","volume":"34","author":"GI Agin-Liebes","year":"2020","unstructured":"Agin-Liebes GI, Malone T, Yalch MM, Mennenga SE, Pont\u00e9 KL, Guss J, et al. Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. J Psychopharmacol. 2020;34:155\u201366.","journal-title":"J Psychopharmacol"},{"key":"944_CR40","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/0269881116675512","volume":"30","author":"S Ross","year":"2016","unstructured":"Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016;30:1165\u201380.","journal-title":"J Psychopharmacol"},{"key":"944_CR41","doi-asserted-by":"publisher","first-page":"14914","DOI":"10.1038\/s41598-019-50612-3","volume":"9","author":"L Smigielski","year":"2019","unstructured":"Smigielski L, Kometer M, Scheidegger M, Kr\u00e4henmann R, Huber T, Vollenweider FX. Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat. Sci Rep. 2019;9:14914.","journal-title":"Sci Rep"},{"key":"944_CR42","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1080\/02791072.2019.1580804","volume":"51","author":"NL Mason","year":"2019","unstructured":"Mason NL, Mischler E, Uthaug MV, Kuypers KPC. Sub-acute effects of psilocybin on empathy, creative thinking, and subjective well-being. J Psychoact Drugs. 2019;51:123\u201334.","journal-title":"J Psychoact Drugs"},{"key":"944_CR43","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.euroneuro.2018.03.016","volume":"28","author":"O Grimm","year":"2018","unstructured":"Grimm O, Kraehenmann R, Preller KH, Seifritz E, Vollenweider FX. Psilocybin modulates functional connectivity of the amygdala during emotional face discrimination. Eur Neuropsychopharmacol. 2018;28:691\u2013700.","journal-title":"Eur Neuropsychopharmacol"},{"key":"944_CR44","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.biopsych.2014.04.010","volume":"78","author":"R Kraehenmann","year":"2015","unstructured":"Kraehenmann R, Preller KH, Scheidegger M, Pokorny T, Bosch OG, Seifritz E, et al. Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers. Biol Psychiatry. 2015;78:572\u201381.","journal-title":"Biol Psychiatry"},{"key":"944_CR45","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1177\/0269881117731279","volume":"32","author":"RR Griffiths","year":"2018","unstructured":"Griffiths RR, Johnson MW, Richards WA, Richards BD, Jesse R, MacLean KA, et al. Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. J Psychopharmacol. 2018;32:49\u201369.","journal-title":"J Psychopharmacol"},{"key":"944_CR46","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1093\/ijnp\/pyx047","volume":"20","author":"T Pokorny","year":"2017","unstructured":"Pokorny T, Preller KH, Kometer M, Dziobek I, Vollenweider FX. Effect of psilocybin on empathy and moral decision-making. Int J Neuropsychopharmacol. 2017;20:747\u201357.","journal-title":"Int J Neuropsychopharmacol"},{"key":"944_CR47","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.neuroimage.2017.07.020","volume":"159","author":"CR Lewis","year":"2017","unstructured":"Lewis CR, Preller KH, Kraehenmann R, Michels L, Staempfli P, Vollenweider FX. Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow. Neuroimage. 2017;159:70\u20138.","journal-title":"Neuroimage"},{"key":"944_CR48","doi-asserted-by":"publisher","first-page":"5119","DOI":"10.1073\/pnas.1524187113","volume":"113","author":"KH Preller","year":"2016","unstructured":"Preller KH, Pokorny T, Hock A, Kraehenmann R, St\u00e4mpfli P, Seifritz E, et al. Effects of serotonin 2A\/1A receptor stimulation on social exclusion processing. Proc Natl Acad Sci USA. 2016;113:5119\u201324.","journal-title":"Proc Natl Acad Sci USA"},{"key":"944_CR49","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","volume":"30","author":"RR Griffiths","year":"2016","unstructured":"Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30:1181\u201397.","journal-title":"J Psychopharmacol"},{"key":"944_CR50","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.1093\/cercor\/bht178","volume":"24","author":"F Bernasconi","year":"2014","unstructured":"Bernasconi F, Schmidt A, Pokorny T, Kometer M, Seifritz E, Vollenweider FX. Spatiotemporal brain dynamics of emotional face processing modulations induced by the serotonin 1A\/2A receptor agonist psilocybin. Cereb Cortex. 2014;24:3221\u201331.","journal-title":"Cereb Cortex"},{"key":"944_CR51","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00213-012-2811-0","volume":"225","author":"A Schmidt","year":"2013","unstructured":"Schmidt A, Kometer M, Bachmann R, Seifritz E, Vollenweider F. The NMDA antagonist ketamine and the 5-HT agonist psilocybin produce dissociable effects on structural encoding of emotional face expressions. Psychopharmacology. 2013;225:227\u201339.","journal-title":"Psychopharmacology"},{"key":"944_CR52","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/npp.2011.261","volume":"37","author":"A Schmidt","year":"2012","unstructured":"Schmidt A, Bachmann R, Kometer M, Csomor PA, Stephan KE, Seifritz E, et al. Mismatch negativity encoding of prediction errors predicts S-ketamine-induced cognitive impairments. Neuropsychopharmacology. 2012;37:865\u201375.","journal-title":"Neuropsychopharmacology"},{"key":"944_CR53","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.biopsych.2012.04.005","volume":"72","author":"M Kometer","year":"2012","unstructured":"Kometer M, Schmidt A, Bachmann R, Studerus E, Seifritz E, Vollenweider FX. Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors. Biol Psychiatry. 2012;72:898\u2013906.","journal-title":"Biol Psychiatry"},{"key":"944_CR54","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","volume":"68","author":"CS Grob","year":"2011","unstructured":"Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstadt AL, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry. 2011;68:71.","journal-title":"Arch Gen Psychiatry"},{"key":"944_CR55","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s00213-011-2358-5","volume":"218","author":"RR Griffiths","year":"2011","unstructured":"Griffiths RR, Johnson MW, Richards WA, Richards BD, McCann U, Jesse R. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology. 2011;218:649\u201365.","journal-title":"Psychopharmacology"},{"key":"944_CR56","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1162\/089892905774597191","volume":"17","author":"OL Carter","year":"2005","unstructured":"Carter OL, Burr DC, Pettigrew JD, Wallis GM, Hasler F, Vollenweider FX. Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors. J Cogn Neurosci. 2005;17:1497\u2013508.","journal-title":"J Cogn Neurosci"},{"key":"944_CR57","unstructured":"Jones NT, Zahid Z, Grady SM, Sultan ZW, Zheng Z, Banks MI, et al. Chronic corticosterone pretreatment reverses psilocybin\u2019s effects on mouse anxious and hedonic behaviors. bioRxiv. 2020;2020.08.12.248229."},{"key":"944_CR58","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1037\/pha0000253","volume":"27","author":"F Sakloth","year":"2019","unstructured":"Sakloth F, Leggett E, Moerke MJ, Townsend EA, Banks ML, Negus SS. Effects of acute and repeated treatment with serotonin 5-HT2A receptor agonist hallucinogens on intracranial self-stimulation in rats. Exp Clin Psychopharmacol. 2019;27:215\u201326.","journal-title":"Exp Clin Psychopharmacol"},{"key":"944_CR59","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1177\/0269881119895520","volume":"34","author":"LJ Mertens","year":"2020","unstructured":"Mertens LJ, Wall MB, Roseman L, Demetriou L, Nutt DJ, Carhart-Harris RL. Therapeutic mechanisms of psilocybin: changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression. J Psychopharmacol. 2020;34:167\u201380.","journal-title":"J Psychopharmacol"},{"key":"944_CR60","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s00213-017-4754-y","volume":"235","author":"JB Stroud","year":"2018","unstructured":"Stroud JB, Freeman TP, Leech R, Hindocha C, Lawn W, Nutt DJ, et al. Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression. Psychopharmacology. 2018;235:459\u201366.","journal-title":"Psychopharmacology"},{"key":"944_CR61","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1177\/0269881117748902","volume":"32","author":"T Lyons","year":"2018","unstructured":"Lyons T, Carhart-Harris RL. Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression. J Psychopharmacol. 2018;32:811\u20139.","journal-title":"J Psychopharmacol"},{"key":"944_CR62","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.neuropharm.2017.12.041","volume":"142","author":"L Roseman","year":"2018","unstructured":"Roseman L, Demetriou L, Wall MB, Nutt DJ, Carhart-Harris RL. Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression. Neuropharmacology. 2018;142:263\u20139.","journal-title":"Neuropharmacology"},{"key":"944_CR63","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","volume":"235","author":"RL Carhart-Harris","year":"2018","unstructured":"Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology. 2018;235:399\u2013408.","journal-title":"Psychopharmacology"},{"key":"944_CR64","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","volume":"3","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris RL, Bolstridge M, Rucker J, Day CMJ, Erritzoe D, Kaelen M, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016;3:619\u201327.","journal-title":"Lancet Psychiatry"},{"key":"944_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100538","volume":"27","author":"BT Anderson","year":"2020","unstructured":"Anderson BT, Danforth A, Daroff PR, Stauffer C, Ekman E, Agin-Liebes G, et al. Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: an open-label safety and feasibility pilot study. EClinicalMedicine. 2020;27: 100538.","journal-title":"EClinicalMedicine."},{"key":"944_CR66","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1177\/0269881118780713","volume":"32","author":"CR Nicholas","year":"2018","unstructured":"Nicholas CR, Henriquez KM, Gassman MC, Cooper KM, Muller D, Hetzel S, et al. High dose psilocybin is associated with positive subjective effects in healthy volunteers. J Psychopharmacol. 2018;32:770\u20138.","journal-title":"J Psychopharmacol"},{"key":"944_CR67","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3109\/00952990.2016.1170135","volume":"43","author":"MW Johnson","year":"2017","unstructured":"Johnson MW, Garcia-Romeu A, Griffiths RR. Long-term follow-up of psilocybin-facilitated smoking cessation. Am J Drug Alcohol Abuse. 2017;43:55\u201360.","journal-title":"Am J Drug Alcohol Abuse"},{"key":"944_CR68","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2174\/1874473708666150107121331","volume":"7","author":"A Garcia-Romeu","year":"2015","unstructured":"Garcia-Romeu A, Griffiths RR, Johnson MW. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Curr Drug Abuse Rev. 2015;7:157\u201364.","journal-title":"Curr Drug Abuse Rev"},{"key":"944_CR69","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1177\/0269881114548296","volume":"28","author":"MW Johnson","year":"2014","unstructured":"Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol. 2014;28:983\u201392.","journal-title":"J Psychopharmacol"},{"key":"944_CR70","first-page":"S90","volume":"40","author":"M Bogenschutz","year":"2015","unstructured":"Bogenschutz M. Mood, craving, and self-efficacy in psilocybin-assisted treatment of alcoholism. Neuropsychopharmacol. 2015;40:S90.","journal-title":"Neuropsychopharmacol"},{"key":"944_CR71","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1038\/s41386-020-0694-z","volume":"45","author":"MW Meinhardt","year":"2020","unstructured":"Meinhardt MW, G\u00fcng\u00f6r C, Skorodumov I, Mertens LJ, Spanagel R. Psilocybin and LSD have no long-lasting effects in an animal model of alcohol relapse. Neuropsychopharmacology. 2020;45:1316\u201322.","journal-title":"Neuropsychopharmacology"},{"key":"944_CR72","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1021\/acschemneuro.9b00493","volume":"11","author":"M Hibicke","year":"2020","unstructured":"Hibicke M, Landry AN, Kramer HM, Talman ZK, Nichols CD. Psychedelics, but not ketamine, produce persistent antidepressant-like effects in a rodent experimental system for the study of depression. ACS Chem Neurosci. 2020;11:864\u201371.","journal-title":"ACS Chem Neurosci"},{"key":"944_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1096\/fasebj.2020.34.s1.02912","volume":"34","author":"M Hibicke","year":"2020","unstructured":"Hibicke M, Nichols C. One dose of psilocybin in late adolescence mitigates deleterious effects of developmental stress on cognition and behavioral despair in adult female rats. Faseb J. 2020;34:1.","journal-title":"Faseb J."},{"key":"944_CR74","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.biopsych.2019.12.027","volume":"88","author":"KH Preller","year":"2020","unstructured":"Preller KH, Duerler P, Burt JB, Ji JL, Adkinson B, St\u00e4mpfli P, et al. Psilocybin induces time-dependent changes in global functional connectivity. Biol Psychiatry. 2020;88:197\u2013207.","journal-title":"Biol Psychiatry"},{"key":"944_CR75","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1097\/FBP.0000000000000394","volume":"29","author":"RR Horsley","year":"2018","unstructured":"Horsley RR, P\u00e1len\u00ed\u010dek T, Kolin J, Vale\u0161 K. Psilocin and ketamine microdosing: effects of subchronic intermittent microdoses in the elevated plus-maze in male Wistar rats. Behav Pharmacol. 2018;29:530\u20136.","journal-title":"Behav Pharmacol"},{"key":"944_CR76","first-page":"233","volume":"19","author":"F Tyls","year":"2016","unstructured":"Tyls F, Palenicek T, Viktorinova M, Prokopcova D, Korcak J, Androvicova R, et al. Psilocybin clinical trial: acute effects and its relationship to the brain activity as measured by quantitative EEG. Int J Neuropsychopharmacol. 2016;19:233.","journal-title":"Int J Neuropsychopharmacol"},{"key":"944_CR77","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1177\/0269881110388326","volume":"25","author":"AL Halberstadt","year":"2011","unstructured":"Halberstadt AL, Koedood L, Powell SB, Geyer MA. Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice. J Psychopharmacol. 2011;25:1548\u201361.","journal-title":"J Psychopharmacol"},{"key":"944_CR78","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00213-007-0930-9","volume":"195","author":"OL Carter","year":"2007","unstructured":"Carter OL, Hasler F, Pettigrew JD, Wallis GM, Liu GB, Vollenweider FX. Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans. Psychopharmacology. 2007;195:415\u201324.","journal-title":"Psychopharmacology"},{"key":"944_CR79","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1038\/sj.npp.1300621","volume":"30","author":"OL Carter","year":"2005","unstructured":"Carter OL, Pettigrew JD, Hasler F, Wallis GM, Liu GB, Hell D, et al. Modulating the rate and rhythmicity of perceptual rivalry alternations with the mixed 5-HT 2A and 5-HT 1A agonist psilocybin. Neuropsychopharmacology. 2005;30:1154\u201362.","journal-title":"Neuropsychopharmacology"},{"key":"944_CR80","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.neulet.2008.02.006","volume":"435","author":"J Wackermann","year":"2008","unstructured":"Wackermann J, Wittmann M, Hasler F, Vollenweider FX. Effects of varied doses of psilocybin on time interval reproduction in human subjects. Neurosci Lett. 2008;435:51\u20135.","journal-title":"Neurosci Lett"},{"key":"944_CR81","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1177\/0269881106065859","volume":"21","author":"M Wittmann","year":"2007","unstructured":"Wittmann M, Carter O, Hasler F, Cahn BR, Grimberg U, Spring P, et al. Effects of psilocybin on time perception and temporal control of behaviour in humans. J Psychopharmacol. 2007;21:50\u201364.","journal-title":"J Psychopharmacol"},{"key":"944_CR82","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00213-003-1640-6","volume":"172","author":"F Hasler","year":"2004","unstructured":"Hasler F, Grimberg U, Benz MA, Huber T, Vollenweider FX. Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose\u2013effect study. Psychopharmacology. 2004;172:145\u201356.","journal-title":"Psychopharmacology"},{"key":"944_CR83","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00221-013-3579-0","volume":"228","author":"BJ Catlow","year":"2013","unstructured":"Catlow BJ, Song S, Paredes DA, Kirstein CL, Sanchez-Ramos J. Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning. Exp Brain Res. 2013;228:481\u201391.","journal-title":"Exp Brain Res"},{"key":"944_CR84","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1159\/000063672","volume":"45","author":"E Gouzoulis-Mayfrank","year":"2002","unstructured":"Gouzoulis-Mayfrank E, Thelen B, Maier S, Heekeren K, Kovar K-A, Sass H, et al. Effects of the hallucinogen psilocybin on covert orienting of visual attention in humans. Neuropsychobiology. 2002;45:205\u201312.","journal-title":"Neuropsychobiology"},{"key":"944_CR85","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0893-133X(98)00089-X","volume":"20","author":"E Gouzoulis-Mayfrank","year":"1999","unstructured":"Gouzoulis-Mayfrank E. Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers: a double-Blind, placebo-controlled PET study with [18F]FDG. Neuropsychopharmacology. 1999;20:565\u201381.","journal-title":"Neuropsychopharmacology"},{"key":"944_CR86","doi-asserted-by":"publisher","first-page":"46421","DOI":"10.1038\/srep46421","volume":"7","author":"MM Schartner","year":"2017","unstructured":"Schartner MM, Carhart-Harris RL, Barrett AB, Seth AK, Muthukumaraswamy SD. Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin. Sci Rep. 2017;7:46421.","journal-title":"Sci Rep"},{"key":"944_CR87","doi-asserted-by":"publisher","first-page":"15171","DOI":"10.1523\/JNEUROSCI.2063-13.2013","volume":"33","author":"SD Muthukumaraswamy","year":"2013","unstructured":"Muthukumaraswamy SD, Carhart-Harris RL, Moran RJ, Brookes MJ, Williams TM, Errtizoe D, et al. Broadband cortical desynchronization underlies the human psychedelic state. J Neurosci. 2013;33:15171\u201383.","journal-title":"J Neurosci"},{"key":"944_CR88","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s002130050860","volume":"142","author":"E Gouzoulis-Mayfrank","year":"1999","unstructured":"Gouzoulis-Mayfrank E, Thelen B, Habermeyer E, Kunert HJ, Kovar K-A, Lindenblatt H, et al. Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers: results of an experimental double-blind placebo-controlled study. Psychopharmacology. 1999;142:41\u201350.","journal-title":"Psychopharmacology"},{"key":"944_CR89","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1038\/sj.npp.1301324","volume":"32","author":"FX Vollenweider","year":"2007","unstructured":"Vollenweider FX, Csomor PA, Knappe B, Geyer MA, Quednow BB. The effects of the preferential 5-HT2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval. Neuropsychopharmacology. 2007;32:1876\u201387.","journal-title":"Neuropsychopharmacology"},{"key":"944_CR90","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/sj.npp.1300005","volume":"28","author":"D Umbricht","year":"2003","unstructured":"Umbricht D, Vollenweider FX, Schmid L, Gr\u00fcbel C, Skrabo A, Huber T, et al. Effects of the 5-HT 2A agonist psilocybin on mismatch negativity generation and AX-continuous performance task: implications for the neuropharmacology of cognitive deficits in schizophrenia. Neuropsychopharmacology. 2003;28:170\u201381.","journal-title":"Neuropsychopharmacology"},{"key":"944_CR91","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/S0006-3223(01)01242-2","volume":"51","author":"D Umbricht","year":"2002","unstructured":"Umbricht D, Koller R, Vollenweider FX, Schmid L. Mismatch negativity predicts psychotic experiences induced by nmda receptor antagonist in healthy volunteers. Biol Psychiatry. 2002;51:400\u20136.","journal-title":"Biol Psychiatry"},{"key":"944_CR92","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","volume":"9","author":"FX Vollenweider","year":"1998","unstructured":"Vollenweider FX, Vollenweider-Scherpenhuyzen MFI, B\u00e4bler A, Vogel H, Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport. 1998;9:3897\u2013902.","journal-title":"NeuroReport"},{"key":"944_CR93","doi-asserted-by":"publisher","first-page":"10544","DOI":"10.1523\/JNEUROSCI.3007-12.2013","volume":"33","author":"M Kometer","year":"2013","unstructured":"Kometer M, Schmidt A, J\u00e4ncke L, Vollenweider FX. Activation of serotonin 2A receptors underlies the psilocybin-induced effects on \u03b1 oscillations, N170 visual-evoked potentials, and visual hallucinations. J Neurosci. 2013;33:10544\u201351.","journal-title":"J Neurosci"},{"key":"944_CR94","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/npp.2011.228","volume":"37","author":"BB Quednow","year":"2012","unstructured":"Quednow BB, Kometer M, Geyer MA, Vollenweider FX. Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers. Neuropsychopharmacology. 2012;37:630\u201340.","journal-title":"Neuropsychopharmacology"},{"key":"944_CR95","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1097\/00001756-200408260-00023","volume":"15","author":"OL Carter","year":"2004","unstructured":"Carter OL, Pettigrew JD, Burr DC, Alais D, Hasler F, Vollenweider FX. Psilocybin impairs high-level but not low-level motion perception. NeuroReport. 2004;15:1947\u201351.","journal-title":"NeuroReport"},{"key":"944_CR96","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3389\/fnbeh.2014.00180","volume":"8","author":"L Rambousek","year":"2014","unstructured":"Rambousek L, Palenicek T, Vales K, Stuchlik A. The effect of psilocin on memory acquisition, retrieval, and consolidation in the rat. Front Behav Neurosci. 2014;8:180.","journal-title":"Front Behav Neurosci"},{"key":"944_CR97","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.602590","volume":"11","author":"D Dudysov\u00e1","year":"2020","unstructured":"Dudysov\u00e1 D, Jank\u016f K, \u0160motek M, Saifutdinova E, Kop\u0159ivov\u00e1 J, Bu\u0161kov\u00e1 J, et al. The effects of daytime psilocybin administration on sleep: implications for antidepressant action. Front Pharmacol. 2020;11: 602590.","journal-title":"Front Pharmacol"},{"key":"944_CR98","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s00213-017-4807-2","volume":"235","author":"A Bravermanov\u00e1","year":"2018","unstructured":"Bravermanov\u00e1 A, Viktorinov\u00e1 M, Tyl\u0161 F, Nov\u00e1k T, Androvi\u010dov\u00e1 R, Kor\u010d\u00e1k J, et al. Psilocybin disrupts sensory and higher order cognitive processing but not pre-attentive cognitive processing: study on P300 and mismatch negativity in healthy volunteers. Psychopharmacology. 2018;235:491\u2013503.","journal-title":"Psychopharmacology"},{"key":"944_CR99","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1038\/s41598-020-59282-y","volume":"10","author":"FS Barrett","year":"2020","unstructured":"Barrett FS, Doss MK, Sepeda ND, Pekar JJ, Griffiths RR. Emotions and brain function are altered up to one month after a single high dose of psilocybin. Sci Rep. 2020;10:2214.","journal-title":"Sci Rep"},{"key":"944_CR100","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.nicl.2015.08.009","volume":"11","author":"R Kraehenmann","year":"2016","unstructured":"Kraehenmann R, Schmidt A, Friston K, Preller KH, Seifritz E, Vollenweider FX. The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity. Neuroimage Clin. 2016;11:53\u201360.","journal-title":"Neuroimage Clin."},{"key":"944_CR101","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.euroneuro.2016.01.005","volume":"26","author":"T Pokorny","year":"2016","unstructured":"Pokorny T, Preller KH, Kraehenmann R, Vollenweider FX. Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A\/2A agonist ergotamine on psilocybin-induced psychedelic experience. Eur Neuropsychopharmacol. 2016;26:756\u201366.","journal-title":"Eur Neuropsychopharmacol"},{"key":"944_CR102","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S0893-133X(98)00108-0","volume":"20","author":"FX Vollenweider","year":"1999","unstructured":"Vollenweider FX, Vontobel P, Hell D, Leenders KL. 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man: a PET study with [11C]raclopride. Neuropsychopharmacology. 1999;20:424\u201333.","journal-title":"Neuropsychopharmacology"},{"key":"944_CR103","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S0893-133X(96)00246-1","volume":"16","author":"F Vollenweider","year":"1997","unstructured":"Vollenweider F. Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology. 1997;16:357\u201372.","journal-title":"Neuropsychopharmacology"},{"key":"944_CR104","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/0006-3223(95)00418-1","volume":"39","author":"M Spitzer","year":"1996","unstructured":"Spitzer M, Thimm M, Hermle L, Holzmann P, Kovar K-A, Heimann H, et al. Increased activation of indirect semantic associations under psilocybin. Biol Psychiatry. 1996;39:1055\u20137.","journal-title":"Biol Psychiatry"},{"key":"944_CR105","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.neuropharm.2015.07.018","volume":"99","author":"A Spain","year":"2015","unstructured":"Spain A, Howarth C, Khrapitchev AA, Sharp T, Sibson NR, Martin C. Neurovascular and neuroimaging effects of the hallucinogenic serotonin receptor agonist psilocin in the rat brain. Neuropharmacology. 2015;99:210\u201320.","journal-title":"Neuropharmacology"},{"key":"944_CR106","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1192\/bjp.bp.111.103309","volume":"200","author":"RL Carhart-Harris","year":"2012","unstructured":"Carhart-Harris RL, Leech R, Williams TM, Erritzoe D, Abbasi N, Bargiotas T, et al. Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin. Br J Psychiatry. 2012;200:238\u201344.","journal-title":"Br J Psychiatry"},{"key":"944_CR107","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1055\/s-2007-979356","volume":"31","author":"E Gouzoulis-Mayfrank","year":"1998","unstructured":"Gouzoulis-Mayfrank E. Methodological issues of human experimental research with hallucinogens. Pharmacopsychiatry. 1998;31:114\u20138.","journal-title":"Pharmacopsychiatry"},{"key":"944_CR108","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1073\/pnas.1119598109","volume":"109","author":"RL Carhart-Harris","year":"2012","unstructured":"Carhart-Harris RL, Erritzoe D, Williams T, Stone JM, Reed LJ, Colasanti A, et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A. 2012;109:2138\u201343.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"944_CR109","doi-asserted-by":"publisher","first-page":"8236","DOI":"10.1038\/s41598-018-26656-2","volume":"8","author":"AS Gabay","year":"2018","unstructured":"Gabay AS, Carhart-Harris RL, Mazibuko N, Kempton MJ, Morrison PD, Nutt DJ, et al. Psilocybin and MDMA reduce costly punishment in the Ultimatum Game. Sci Rep. 2018;8:8236.","journal-title":"Sci Rep"},{"key":"944_CR110","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3390\/biomedicines8020034","volume":"8","author":"CR Lewis","year":"2020","unstructured":"Lewis CR, Preller KH, Braden BB, Riecken C, Vollenweider FX. Rostral anterior cingulate thickness predicts the emotional psilocybin experience. Biomedicines. 2020;8:34.","journal-title":"Biomedicines."},{"key":"944_CR111","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1002\/hbm.22833","volume":"36","author":"AV Lebedev","year":"2015","unstructured":"Lebedev AV, L\u00f6vd\u00e9n M, Rosenthal G, Feilding A, Nutt DJ, Carhart-Harris RL. Finding the self by losing the self: Neural correlates of ego-dissolution under psilocybin. Hum Brain Mapp. 2015;36:3137\u201353.","journal-title":"Hum Brain Mapp"},{"key":"944_CR112","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.pnpbp.2019.01.002","volume":"92","author":"B Cao","year":"2019","unstructured":"Cao B, Zhu J, Zuckerman H, Rosenblat JD, Brietzke E, Pan Z, et al. Pharmacological interventions targeting anhedonia in patients with major depressive disorder: a systematic review. Prog Neuropsychopharmacol Biol Psychiatry. 2019;92:109\u201317.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"944_CR113","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3389\/fpsyt.2019.00311","volume":"10","author":"M Destoop","year":"2019","unstructured":"Destoop M, Morrens M, Coppens V, Dom G. Addiction, anhedonia, and comorbid mood disorder: a narrative review. Front Psychiatry. 2019;10:311.","journal-title":"Front Psychiatry."},{"key":"944_CR114","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1001\/jamapsychiatry.2015.0071","volume":"72","author":"RH Kaiser","year":"2015","unstructured":"Kaiser RH, Andrews-Hanna JR, Wager TD, Pizzagalli DA. Large-scale network dysfunction in major depressive disorder: a meta-analysis of resting-state functional connectivity. JAMA Psychiat. 2015;72:603\u201311.","journal-title":"JAMA Psychiat"},{"key":"944_CR115","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.neubiorev.2015.01.019","volume":"51","author":"L Nawijn","year":"2015","unstructured":"Nawijn L, van Zuiden M, Frijling JL, Koch SBJ, Veltman DJ, Olff M. Reward functioning in PTSD: A systematic review exploring the mechanisms underlying anhedonia. Neurosci Biobehav Rev. 2015;51:189\u2013204.","journal-title":"Neurosci Biobehav Rev"},{"key":"944_CR116","doi-asserted-by":"publisher","first-page":"e469","DOI":"10.1038\/tp.2014.105","volume":"4","author":"N Lally","year":"2014","unstructured":"Lally N, Nugent AC, Luckenbaugh DA, Ameli R, Roiser JP, Zarate CA. Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression. Transl Psychiatry. 2014;4:e469\u2013e469.","journal-title":"Transl Psychiatry"},{"key":"944_CR117","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jaac.2012.01.011","volume":"51","author":"DL McMakin","year":"2012","unstructured":"McMakin DL, Olino TM, Porta G, Dietz LJ, Emslie G, Clarke G, et al. Anhedonia predicts poorer recovery among youth with selective serotonin reuptake inhibitor treatment-resistant depression. J Am Acad Child Adolesc Psychiatry. 2012;51:404\u201311.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"944_CR118","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1177\/0269881106069938","volume":"21","author":"D Nutt","year":"2007","unstructured":"Nutt D, Demyttenaere K, Janka Z, Aarre T, Bourin M, Canonico PL, et al. The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. J Psychopharmacol. 2007;21:461\u201371.","journal-title":"J Psychopharmacol"},{"key":"944_CR119","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1176\/appi.ajp.2007.07101581","volume":"165","author":"C Grillon","year":"2008","unstructured":"Grillon C, Lissek S, Rabin S, McDowell D, Dvir S, Pine DS. Increased anxiety during anticipation of unpredictable but not predictable aversive stimuli as a psychophysiologic marker of panic disorder. Am J Psychiatry. 2008;165:898\u2013904.","journal-title":"Am J Psychiatry"},{"key":"944_CR120","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/S0006-3223(99)00144-4","volume":"47","author":"T Peri","year":"2000","unstructured":"Peri T, Ben-Shakhar G, Orr SP, Shalev AY. Psychophysiologic assessment of aversive conditioning in posttraumatic stress disorder. Biol Psychiatry. 2000;47:512\u20139.","journal-title":"Biol Psychiatry"},{"key":"944_CR121","doi-asserted-by":"publisher","first-page":"733","DOI":"10.3389\/fphar.2018.00733","volume":"9","author":"EE Schenberg","year":"2018","unstructured":"Schenberg EE. Psychedelic-assisted psychotherapy: a paradigm shift in psychiatric research and development. Front Pharmacol. 2018;9:733.","journal-title":"Front Pharmacol"},{"key":"944_CR122","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.tips.2008.06.006","volume":"29","author":"MA Geyer","year":"2008","unstructured":"Geyer MA, Vollenweider FX. Serotonin research: contributions to understanding psychoses. Trends Pharmacol Sci. 2008;29:445\u201353.","journal-title":"Trends Pharmacol Sci"},{"key":"944_CR123","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1471-2202-5-42","volume":"5","author":"G Tononi","year":"2004","unstructured":"Tononi G. An information integration theory of consciousness. BMC Neurosci. 2004;5:42.","journal-title":"BMC Neurosci"},{"key":"944_CR124","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/S0361-9230(01)00646-3","volume":"56","author":"FX Vollenweider","year":"2001","unstructured":"Vollenweider FX, Geyer MA. A systems model of altered consciousness: integrating natural and drug-induced psychoses. Brain Res Bull. 2001;56:495\u2013507.","journal-title":"Brain Res Bull"},{"key":"944_CR125","doi-asserted-by":"publisher","unstructured":"Halpern JH, Lerner AG, Passie T. A review of hallucinogen persisting perception disorder (HPPD) and an exploratory study of subjects claiming symptoms of HPPD. In: Halberstadt AL, Vollenweider FX, Nichols DE, editors. Behavioral neurobiology of psychedelic drugs. Berlin, Heidelberg: Springer; 2018. p. 333\u201360. https:\/\/doi.org\/10.1007\/7854_2016_457.","DOI":"10.1007\/7854_2016_457"},{"key":"944_CR126","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s00213-018-5106-2","volume":"236","author":"T Anderson","year":"2019","unstructured":"Anderson T, Petranker R, Rosenbaum D, Weissman CR, Dinh-Williams L-A, Hui K, et al. Microdosing psychedelics: personality, mental health, and creativity differences in microdosers. Psychopharmacology. 2019;236:731\u201340.","journal-title":"Psychopharmacology"},{"key":"944_CR127","unstructured":"Fadiman J. The psychedelic explorer\u2019s guide: safe, therapeutic, and sacred journeys. Simon and Schuster; 2011."},{"key":"944_CR128","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.concog.2005.06.004","volume":"14","author":"RJR Blair","year":"2005","unstructured":"Blair RJR. Responding to the emotions of others: dissociating forms of empathy through the study of typical and psychiatric populations. Conscious Cogn. 2005;14:698\u2013718.","journal-title":"Conscious Cogn"},{"key":"944_CR129","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1097\/HRP.0000000000000260","volume":"28","author":"RM Salgado","year":"2020","unstructured":"Salgado RM, Pedrosa R, Bastos-Leite AJ. Dysfunction of empathy and related processes in borderline personality disorder: a systematic review. Harv Rev Psychiatry. 2020;28:238\u201354.","journal-title":"Harv Rev Psychiatry"},{"key":"944_CR130","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.neubiorev.2013.01.024","volume":"37","author":"P Thoma","year":"2013","unstructured":"Thoma P, Friedmann C, Suchan B. Empathy and social problem solving in alcohol dependence, mood disorders and selected personality disorders. Neurosci Biobehav Rev. 2013;37:448\u201370.","journal-title":"Neurosci Biobehav Rev"},{"key":"944_CR131","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.biopsych.2010.10.002","volume":"69","author":"M Kometer","year":"2011","unstructured":"Kometer M, Cahn BR, Andel D, Carter OL, Vollenweider FX. The 5-HT2A\/1A agonist psilocybin disrupts modal object completion associated with visual hallucinations. Biol Psychiatry. 2011;69:399\u2013406.","journal-title":"Biol Psychiatry"},{"key":"944_CR132","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0301-0511(01)00090-4","volume":"57","author":"D Riemann","year":"2001","unstructured":"Riemann D, Berger M, Voderholzer U. Sleep and depression: results from psychobiological studies: an overview. Biol Psychol. 2001;57:67\u2013103.","journal-title":"Biol Psychol"},{"key":"944_CR133","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.661233","author":"R Ko\u010d\u00e1rov\u00e1","year":"2021","unstructured":"Ko\u010d\u00e1rov\u00e1 R, Hor\u00e1\u010dek J, Carhart-Harris R. Does psychedelic therapy have a transdiagnostic action and prophylactic potential? Front Psychiatry. 2021. https:\/\/doi.org\/10.3389\/fpsyt.2021.661233.","journal-title":"Front Psychiatry."},{"key":"944_CR134","unstructured":"Reeves B, Deeks, Higgins J, Shea, Tugwell P, Wells G. Chapter 24: including non-randomized studies on intervention effects in Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. https:\/\/training.cochrane.org\/handbook\/current\/chapter-24. Accessed 17 May 2022."},{"key":"944_CR135","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1021\/cn300138m","volume":"4","author":"JB Hanks","year":"2012","unstructured":"Hanks JB, Gonz\u00e1lez-Maeso J. Animal models of serotonergic psychedelics. ACS Chem Neurosci. 2012;4:33\u201342.","journal-title":"ACS Chem Neurosci"},{"key":"944_CR136","first-page":"5","volume":"2","author":"T Denayer","year":"2014","unstructured":"Denayer T, St\u00f6hr T, Van Roy M. Animal models in translational medicine: validation and prediction. New Horizons Transl Med. 2014;2:5\u201311.","journal-title":"New Horizons Transl Med."},{"key":"944_CR137","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.jad.2018.08.073","volume":"241","author":"Y Lee","year":"2018","unstructured":"Lee Y, Ragguett R-M, Mansur RB, Boutilier JJ, Rosenblat JD, Trevizol A, et al. Applications of machine learning algorithms to predict therapeutic outcomes in depression: a meta-analysis and systematic review. J Affect Disord. 2018;241:519\u201332.","journal-title":"J Affect Disord"},{"key":"944_CR138","doi-asserted-by":"publisher","DOI":"10.1016\/j.artmed.2019.101704","volume":"99","author":"AMY Tai","year":"2019","unstructured":"Tai AMY, Albuquerque A, Carmona NE, Subramanieapillai M, Cha DS, Sheko M, et al. Machine learning and big data: implications for disease modeling and therapeutic discovery in psychiatry. Artif Intell Med. 2019;99: 101704.","journal-title":"Artif Intell Med"},{"key":"944_CR139","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1017\/neu.2019.15","volume":"31","author":"O Jefsen","year":"2019","unstructured":"Jefsen O, H\u00f8jgaard K, Christiansen SL, Elfving B, Nutt DJ, Wegener G, et al. Psilocybin lacks antidepressant-like effect in the Flinders Sensitive Line rat. Acta Neuropsychiatr C. 2019;31:213\u20139.","journal-title":"Acta Neuropsychiatr. C"},{"key":"944_CR140","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1097\/00008877-200403000-00007","volume":"15","author":"WE Fantegrossi","year":"2004","unstructured":"Fantegrossi WE, Woods JH, Winger G. Transient reinforcing effects of phenylisopropylamine and indolealkylamine hallucinogens in rhesus monkeys. Behav Pharmacol. 2004;15:149\u201357.","journal-title":"Behav Pharmacol"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-022-00944-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-022-00944-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-022-00944-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T22:24:10Z","timestamp":1665440650000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-022-00944-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,12]]},"references-count":140,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["944"],"URL":"https:\/\/doi.org\/10.1007\/s40263-022-00944-y","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,12]]},"assertion":[{"value":"17 July 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.\u00a0Open access funding provided by University of Zurich.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"NP received a salary from the RECONNECT Foundation for Pharmaceutical Development of Ayahuasca as part of an ongoing clinical study, Zurich, Switzerland and was employed as the responsible pharmacist at Aracell Zist Darou Pharmaceutical. ZHK is currently employed by Bayer Pharmaceutical, Iran and has received no funding, financial, or infrastructure support for this project from Bayer Pharmaceutical. YL received salary support from the Global Alliance for Chronic Diseases\/Canadian Institutes of Health Research\/National Natural Science Foundation of China\u2019s Mental Health Team Grant and the Canadian Institutes of Health Research Frederick Banting and Charles Best Canada Graduate Scholarship; and personal fees from Braxia Scientific Corp. KT has received personal fees from Braxia Scientific Corp. JDR is the medical director and chief medical and scientific officer of Braxia Health (formally known as the Canadian Rapid Treatment Center of Excellence and is a fully owned subsidiary of Braxia Scientific Corp), which provides ketamine and esketamine treatment for depression; he has received research grant support from the Canadian Institute of Health Research, American Psychiatric Association, American Society of Psychopharmacology, Canadian Cancer Society, Canadian Psychiatric Association, Joseph M. West Family Memorial Fund, Timeposters Fellowship, University Health Network Centre for Mental Health, and the University of Toronto and speaking, consultation, or research fees from Allergan, COMPASS, Janssen, Lundbeck, and Sunovion. DC has received grant monies for research from Eli Lilly, Janssen Cilag, Roche, Allergen, Bristol-Myers Squibb, Pfizer, Lundbeck, Astra Zeneca, and Hospira; travel support and honoraria for talks and consultancy from Eli Lilly, Bristol-Myers Squibb, Astra Zeneca, Lundbeck, Janssen Cilag,Pfizer, Organon, Sanofi-Aventis, Wyeth, Hospira, Servier, and Seqirus; and is a current or past advisory board member for Lu AA21004: Lundbeck; Varenicline: Pfizer; Asenapine: Lundbeck; Aripiprazole LAI: Lundbeck; Lisdexamfetamine: Shire; Lurasidone: Servier; Brexpiprazole: Lundbeck; Treatment Resistant Depression: LivaNova; Cariprazine: Seqirus. He is founder of the Optimal Health Program, currently operating as Optimal Health Australia; and is part owner of Clarity Healthcare. He is on the scientific advisory of The Mental Health Foundation of Australia. He does not knowingly have stocks or shares in any pharmaceutical company. RSM has received research grant support from the Global Alliance for Chronic Diseases\/Canadian Institutes of Health Research\/National Natural Science Foundation of China\u2019s Mental Health Team Grant; and speaker\/consultation fees from Lundbeck, Janssen, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, and Abbvie. RSM is a CEO of Braxia Scientific Corp. FY, LL, MS, KL, FN, NR, HG, OL, BC, and RH have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"NP and RSM developed the idea of the RDoC-based framework. NP designed the methodology for screening, data categorization, and tabulation. NP, ZHK, and FYS carried out the screening. NP, ZHK, and FYS prepared the visualizations. NP and RSM wrote the paper. NP and FYS edited the revised manuscript. All authors viewed and approved the final manuscript, agree to be accountable for the work, and had the opportunity to comment on earlier drafts.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}